Venmax Drugs and Pharmaceuticals Ltd

Two companies are seeking approval for a Composite Scheme of Amalgamation, with one company to be absorbed into the other. The National Company Law Tribunal (NCLT) has dispensed with the need for meetings for shareholders and creditors of both entities, but a meeting is required for shareholders of the Transferee Company on October 24, 2026, at the company’s registered office in Hyderabad, accessible via video conferencing. Ms. Sarvani Desiraju will chair the meeting, with Ms. Kruthi Kalaga serving as the scrutinizer, receiving remuneration of Rs 1,50,000 and Rs 75,000 respectively. Shareholders of the Transferee Company will receive notice 30 days prior, and a share exchange ratio of one share for one share will be implemented, with new shares carrying equivalent rights.

Venmax Drugs & Pharmaceuticals Limited will hold a board meeting on August 31, 2026, at 4:30 P.M. to discuss the notice, directors' report, and annual report for the financial year 2025-26, as well as to decide on the date, time, and venue of the 37th Annual General Meeting.

Venmax Drugs & Pharmaceuticals Limited stated there was no deviation or variation in the use of Rs 20.05 crore raised through the issue of fully convertible equity warrants on a preferential basis, according to a regulatory filing with the BSE Limited on August 7, 2026; Rs 12.69 crore was received against 63,44,000 warrant conversions and Rs 1.84 crore against 36,81,000 warrant conversions, with Rs 8.37 crore utilized for working capital and Rs 0.20 crore for general corporate purposes and business acquisition as of June 30, 2026.

Venmax Drugs and Pharmaceuticals Limited will hold a board meeting on Friday, August 7, 2026, at 4:00 P.M. to consider and approve the unaudited financial results for the quarter ended June 30, 2026, and the forfeiture of partly paid-up share warrants. The trading window for the company’s securities will remain closed for designated persons from July 1, 2026, until August 9, 2026.

Venmax Drugs and Pharmaceuticals Limited has allotted 7,53,334 equity shares at a price of Rs 20 each to Dinesh Muddu Kotian, following the conversion of an equal number of warrants. The company received Rs 1,13,00,10 for the allotment, increasing its paid-up capital to Rs 14,48,39,290 comprising 1,44,83,929 equity shares. Out of the total 1,00,25,000 warrants initially issued, 7,80,001 remain outstanding for conversion.

Venmax Drugs and Pharmaceuticals Limited announced the allotment of 21,47,665 equity shares at a price of Rs 20 each to warrant holders, following the exercise of convertible warrants. The company received Rs 3,22,14,975 from the allotment, increasing its paid-up capital to Rs 13,73,05,950 comprising 1,37,30,595 equity shares. Eight warrant holders, including Dinesh Dayaram Dhanak & Deepti Dinesh Dhanak, Nitesh Niranjan Jha, Umesh Bikhchand Bijlani, Dinakara Sateesha, Deepak Pandurang Bhojane, Trupti Uday Khanapurkar, Jigna Pravinkumar Raval, and Dinesh Muddu Kotian, participated in the conversion.

Net profit of Venmax Drugs & Pharmaceuticals declined 85.90% to Rs 0.11 crore in the quarter ended March 2026 as against Rs 0.78 crore during the previous quarter ended March 2025. Sales rose 1093.94% to Rs 3.94 crore in the quarter ended March 2026 as against Rs 0.33 crore during the previous quarter ended March 2025. For the full year,net profit reported to Rs 0.25 crore in the year ended March 2026 as against net loss of Rs 0.01 crore during the previous year ended March 2025. Sales rose 890.12% to Rs 8.02 crore in the year ended March 2026 as against Rs 0.81 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales3.940.33 1094 8.020.81 890 OPM %0.51-72.73 -1.50-129.63 - PBDT0.110.78 -86 0.280 0 PBT0.110.78 -86 0.28-0.01 LP NP0.110.78 -86 0.25-0.01 LP Powered by Capital Market - Live

Venmax Drugs & Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 14 May 2026.

Net profit of Venmax Drugs & Pharmaceuticals reported to Rs 0.03 crore in the quarter ended December 2025 as against net loss of Rs 0.50 crore during the previous quarter ended December 2024. Sales rose 675.00% to Rs 1.55 crore in the quarter ended December 2025 as against Rs 0.20 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales1.550.20 675 OPM %-1.94-250.00 - PBDT0.04-0.50 LP PBT0.04-0.50 LP NP0.03-0.50 LP Powered by Capital Market - Live

Venmax Drugs & Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 7 February 2026.Powered by Capital Market - Live